Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
Wiener klinische Wochenschrift
Erschienen in:

01.04.2016 | leitlinien für die praxis

Geriatrische Aspekte bei Diabetes mellitus

verfasst von: Joakim Huber, Michael Smeikal, Monika Lechleitner, Peter Fasching

Erschienen in: Wiener klinische Wochenschrift | Sonderheft 2/2016

Einloggen, um Zugang zu erhalten

Zusammenfassung

Es besteht eine hohe Prävalenz an Diabetes mellitus Typ 2 bei über 70-Jährigen in industrialisierten Ländern. Dieser Artikel enthält Empfehlungen für die Diagnose, die Prävention und die Therapieziele in der Behandlung des älteren diabetischen Patienten anhand der aktuellen Evidenzlage.
Vorheriger Artikel Diabetes mellitus im Kindes- und Jugendalter
Nächster Artikel Ernährungsempfehlungen bei Diabetes mellitus
Literatur
1.
Rathmann W, Haastert B, Icks A, et al. High prevalence of undiagnosed diabetes mellitus in Southern Germany: target populations for efficient screening. The KORA survey 2000. Diabetologia. 2003;46:182–9.PubMed
2.
DECODE Study Group. Age- and sex-specific prevalences of diabetes and impaired glucose regulation in 13 European cohorts. Diabetes Care. 2003;26:61–9.CrossRef
3.
Resnick HE, Harris MI, Brock DB, Harris TB. American Diabetes Association diabetes diagnostic criteria, advancing age, and cardiovascular disease risk profiles: results from the Third National Health and Nutrition Examination Survey. Diabetes Care. 2000;23:176–80.CrossRefPubMed
4.
Hauner H, Kurnaz AA, Haastert B, Groschopp C, Feldhoff KH. Undiagnosed diabetes mellitus and metabolic control assessed by HbA(1c) among residents of nursing homes. Exp Clin Endocrinol Diabetes. 2001;109:326–9.CrossRefPubMed
5.
American Diabetes Association. Standards of medical care in diabetes – 2011. Diabetes Care. 2011;34 Suppl 1:S11–61.CrossRefPubMedCentral
6.
American Diabetes Association. (2) classification and diagnosis of diabetes. Diabetes Care. 201 5;38 Suppl 1:S8–16.
7.
Bethel MA, Sloan FA, Belsky D, Feinglos MN. Longitudinal incidence and prevalence of adverse outcomes of diabetes mellitus in elderly patients. Arch Intern Med. 2007;167:921–7.CrossRefPubMed
8.
Rosenthal MJ, Fajardo M, Gilmore S, Morley JE, Naliboff BD. Hospitalization and mortality of diabetes in older adults. A 3-year prospective study. Diabetes Care. 1998;21:231–5.CrossRefPubMed
9.
Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403.CrossRefPubMed
10.
Jefferis BJ, Whincup PH, Lennon L, Wannamethee SG. Longitudinal associations between changes in physical activity and onset of type 2 diabetes in older British men: the influence of adiposity. Diabetes Care. 2012;35:1876–83.CrossRefPubMedPubMedCentral
11.
Villareal DT, Chode S, Parimi N, et al. Weight loss, exercise, or both and physical function in obese older adults. N Engl J Med. 2011;364:1218–29.CrossRefPubMedPubMedCentral
12.
Meneilly GS, Knip A, Tessier D. Diabetes in the elderly. Can J Diabetes. 2013;37 Suppl 1:S184–90.CrossRefPubMed
13.
Evans WJ. Protein nutrition, exercise and aging. J Am Coll Nutr. 2004;23:601–9.CrossRef
14.
Huang ES, Liu JY, Moffet HH, John PM, Karter AJ. Glycemic control, complications, and death in older diabetic patients: the diabetes and aging study. Diabetes Care. 2011;34:1329–36.CrossRefPubMedPubMedCentral
15.
Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59.CrossRefPubMed
16.
Tan HH, McAlpine RR, James P, et al. Diagnosis of type 2 diabetes at an older age: effect on mortality in men and women. Diabetes Care. 2004;27:2797–9.CrossRefPubMed
17.
Zeyfang A, Braun A. [Guidelines „Diabetes mellitus in the elderly“]. MMW Fortschr Med. 2009;151:33–5, 37.PubMed
18.
Zeyfang A, Bahrmann A, Wernecke J. Diabetes mellitus im Alter. Diabetologie. 2014;9:189–95.
19.
Siegmund T, Schumm-Draeger PM. Therapie mit oralen Antidiabetika und/oder Insulin im höheren Alter? Diabetologe. 2010;6:560–9.CrossRef
20.
Bertoni AG, Krop JS, Anderson GF, Brancati FL. Diabetes-related morbidity and mortality in a national sample of U.S. elders. Diabetes Care. 2002;25:471–5.CrossRefPubMed
21.
Gregg EW, Beckles GL, Williamson DF, et al. Diabetes and physical disability among older U.S. adults. Diabetes Care. 2000;23:1272–7.CrossRefPubMed
22.
Krop JS, Powe NR, Weller WE, Shaffer TJ, Saudek CD, Anderson GF. Patterns of expenditures and use of services among older adults with diabetes. Implications for the transition to capitated managed care. Diabetes Care. 1998;21:747–52.CrossRefPubMed
23.
Rawlings AM, Sharrett AR, Schneider AL, et al. Diabetes in midlife and cognitive change over 20 years: a cohort study. Ann Intern Med. 161:785–93.
24.
Cheng G, Huang C, Deng H, Wang H. Diabetes as a risk factor for dementia and mild cognitive impairment: a meta-analysis of longitudinal studies. Intern Med J. 2012;42:484–91.CrossRefPubMed
25.
Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289:3095–105.CrossRefPubMed
26.
Katon W, Pedersen HS, Ribe AR, et al. Effect of depression and diabetes mellitus on the risk for dementia: a national population-based cohort study. JAMA Psychiatry. 2015;72:612–9.CrossRefPubMed
27.
van Dooren FE, Nefs G, Schram MT, Verhey FR, Denollet J, Pouwer F. Depression and risk of mortality in people with diabetes mellitus: a systematic review and meta-analysis. PLoS One 2013;8:e57058.CrossRefPubMedPubMedCentral
28.
Black SA, Markides KS, Ray LA. Depression predicts increased incidence of adverse health outcomes in older Mexican Americans with type 2 diabetes. Diabetes Care. 2003;26:2822–8.CrossRefPubMed
29.
Kimbro LB, Mangione CM, Steers WN, et al. Depression and all-cause mortality in persons with diabetes mellitus: are older adults at higher risk? Results from the translating research into action for diabetes study. J Am Geriatr Soc. 2014;62:1017–22.CrossRefPubMedPubMedCentral
30.
Abbatecola AM, Rizzo MR, Barbieri M, et al. Postprandial plasma glucose excursions and cognitive functioning in aged type 2 diabetics. Neurology. 2006;67:235–40.CrossRefPubMed
31.
Bremer JP, Jauch-Chara K, Hallschmid M, Schmid S, Schultes B. Hypoglycemia unawareness in older compared with middle-aged patients with type 2 diabetes. Diabetes Care. 2009;32:1513–7.CrossRefPubMedPubMedCentral
32.
Whitmer RA, Karter AJ, Yaffe K, Quesenberry CP Jr, Selby JV. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA. 2009;301:1565–72.CrossRefPubMedPubMedCentral
33.
Punthakee Z, Miller ME, Launer LJ, et al. Poor cognitive function and risk of severe hypoglycemia in type 2 diabetes: post hoc epidemiologic analysis of the ACCORD trial. Diabetes Care. 2012;35:787–93.CrossRefPubMedPubMedCentral
34.
Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575–85.CrossRefPubMed
35.
Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887–98.CrossRefPubMed
36.
Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289:2560–72.CrossRefPubMed
37.
Mancia G, Fagard R, Narkiewicz K, et al. ESH/ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281–357.CrossRefPubMed
38.
Schafer HH, De Villiers JN, Sudano I, et al. Recommendations for the treatment of hypertension in the elderly and very elderly ‒ a scotoma within international guidelines. Swiss Med Wkly. 2012;142:w13574.PubMed
39.
Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22.CrossRef
40.
Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623–30.CrossRefPubMed
41.
Forman D, Wenger NK. What do the recent American Heart Association/American College of Cardiology Foundation Clinical Practice Guidelines tell us about the evolving management of coronary heart disease in older adults? J Geriatr Cardiol. 2013;10:123–8.PubMedPubMedCentral
42.
Donnan PT, MacDonald TM, Morris AD. Adherence to prescribed oral hypoglycaemic medication in a population of patients with Type 2 diabetes: a retrospective cohort study. Diabet Med. 2002;19:279–84.CrossRefPubMed
43.
44.
Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone clinical trial in macroVascular events): a randomised controlled trial. Lancet. 2005;366:1279–89.CrossRefPubMed
45.
Stafford S, Elahi D, Meneilly GS. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin in older adults with type 2 diabetes mellitus. J Am Geriatr Soc. 2011;59:1148–9.CrossRefPubMed
46.
Barzilai N, Guo H, Mahoney EM, et al. Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Curr Med Res Opin. 2011;27:1049–58.CrossRefPubMed
47.
Schwartz SL. Treatment of elderly patients with type 2 diabetes mellitus: a systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors. Am J Geriatr Pharmacother. 2010;8:405–18.CrossRefPubMed
48.
Pratley RE, McCall T, Fleck PR, Wilson CA, Mekki Q. Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies. J Am Geriatr Soc. 2009;57:2011–9.CrossRefPubMed
49.
DeFronzo RA, Fleck PR, Wilson CA, Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care. 2008;31:2315–7.CrossRefPubMedPubMedCentral
50.
Barnett AH. The role of GLP-1 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutide. Diabetes Obes Metab. 2012;14:304–14.CrossRefPubMedPubMedCentral
51.
Graefe-Mody U, Friedrich C, Port A, et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin(*). Diabetes Obes Metab. 2011;13:939–46.CrossRefPubMed
52.
Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696–705.CrossRefPubMed
53.
Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol. 2012;8:495–502.CrossRefPubMed
54.
Bakris GL, Fonseca VA, Sharma K, Wright EM. Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int. 2009;75:1272–7.CrossRefPubMed
55.
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–28.CrossRefPubMed
56.
Monami M, Nardini C, Mannucci E. Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2014;16:457–66.CrossRefPubMed
57.
Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, List JF. Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. J Diabetes Complications. 2013;27:479–84.CrossRefPubMed
58.
Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, List JF. Urinary tract infections in patients with diabetes treated with dapagliflozin. J Diabetes Complications. 2013;27:473–8.CrossRefPubMed
59.
Nyirjesy P, Sobel JD, Fung A, et al. Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Curr Med Res Opin. 2014;30:1109–19.CrossRefPubMed
60.
Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013;382:941–50.CrossRefPubMed
61.
Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care. 2013;36:2508–15.CrossRefPubMedPubMedCentral
62.
Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013;159:262–74.CrossRefPubMed
63.
Braun AK, Kubiak T, Kuntsche J, et al. SGS: a structured treatment and teaching programme for older patients with diabetes mellitus ‒ a prospective randomised controlled multi-centre trial. Age Ageing. 2009;38:390–6.CrossRefPubMedPubMedCentral
64.
Scherbaum WA, Kerner W, Hader C, Gräf-Gruss R. Für die DGG/ÖGGG „Praxis-Leitlinie: Diabetes im Alter.“ Eur J Geriatr. 2006;8:231–5.
65.
Zeyfang A. [Practical aspects of diabetes care in the elderly]. MMW Fortschr Med. 2009;151:40–2.PubMed
66.
Sinclair A, Morley JE, Rodriguez-Manas L, et al. Diabetes mellitus in older people: position statement on behalf of the International Association of Gerontology and Geriatrics (IAGG), the European Diabetes Working Party for Older People (EDWPOP), and the International Task Force of Experts in Diabetes. J Am Med Dir Assoc. 2012;13:497–502.CrossRefPubMed
67.
American Diabetes Association. Standards of medical care in diabetes ‒ 2015: summary of revisions. Diabetes Care. 2015;38 Suppl 1:S4.
68.
American Diabetes Association. (10) Older adults. Diabetes Care. 2015;38 Suppl 1:S67–9.CrossRef
69.
Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140–9.CrossRefPubMed
Metadaten
Titel
Geriatrische Aspekte bei Diabetes mellitus
verfasst von
Joakim Huber
Michael Smeikal
Monika Lechleitner
Peter Fasching
Publikationsdatum
01.04.2016
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe Sonderheft 2/2016
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-016-0955-3

Weitere Artikel der Sonderheft 2/2016

Exokrine Pankreasinsuffizienz und Diabetes mellitus

  • leitlinien für die praxis

Antihyperglykämische Therapie bei Diabetes mellitus Typ 2

  • leitlinien für die praxis

Austrian Lipid Consensus on the management of metabolic lipid disorders to prevent vascular complications

  • Open Access
  • austrian lipid consensus

Blutzuckerselbstkontrolle

  • leitlinien für die praxis

Diabetes mellitus – Definition, Klassifikation und Diagnose

  • leitlinien für die praxis

Diabetische Nierenerkrankung – Update 2016

  • Open Access
  • leitlinien für die praxis